CureVac Publishes Detailed Interim Data from the Phase 1 Study of its COVID-19 Vaccine Candidate CVnCoV

TÜBINGEN, Germany / BOSTON, USA - November 10, 2020 -- CureVac NV (Nasdaq: CVAC), a biopharmaceutical company developing a new class of drugs based on messenger ribonucleic acid (mRNA) in clinical trials, today announced detailed interim data on phase 1 of its COVID-19 vaccine candidate CVnCoV. On November 2, 2020, the company had already published the first positive study results. The manuscript can be called up on the medRxiv pre-print server. In addition, it will be submitted for publication in a peer-reviewed journal.

The previously announced interim data showed that CVnCoV is well tolerated in all tested dose levels between 2 and 12 µg and induces high binding and neutralizing antibody levels. There were also signs of T cell activation. The quality of the immune response corresponds to the immune response observed in recovered COVID-19 patients and is comparable to a natural COVID-19 infection.

CureVac will announce further details of the detailed interim phase 1 study dates in a conference call and webcast today at 5 p.m. CET. The link to the webcast and the accompanying presentation can be found in the Investor Relations area on the CureVac website: https://www.curevac.com/newsroom/events/

About CVnCoV
 
CureVac began developing its mRNA-based vaccine candidate COVID-19 in January 2020. The active ingredient is based on optimized, chemically unmodified mRNA that codes for the prefusion-stabilized full spike protein of the SARS-CoV-2 virus. In June 2020, the company started a clinical phase 1 study with CVnCoV in clinical study centers in Germany and Belgium in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). At the end of September 2020, the vaccine candidate started a phase 2a clinical trial in Peru and Panama, in which clinical investigations were extended to older adults and regions with a high incidence of COVID-19 infections. The company plans to initiate a pivotal phase 2b / 3 clinical trial by the end of 2020. The material for the clinical studies is provided thanks to the company's extensive production capacities for mRNA vaccines at its headquarters in Tübingen. CureVac is currently expanding this manufacturing capacity to prepare the large-scale manufacture of CVnCoV for possible commercial delivery.
About CureVac
 
CureVac is a global biopharmaceutical company in the field of mRNA technology (messenger RNA) with more than 20 years of experience in the development and optimization of this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is based on the use of chemically unmodified mRNA as a data carrier to guide the human body to produce the correspondingly encoded proteins with which a variety of diseases can be combated. Based on its proprietary technology, the company has built an extensive clinical pipeline in the areas of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases. CureVac has been listed on the New York Nasdaq since August 2020. The company is headquartered in Tübingen, Germany, and employs more than 500 people in Tübingen, Frankfurt and Boston, USA. For more information, seewww.curevac.com .

Source: CureVac

Posted: November 2020